PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is expected to be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

PDS Biotechnology Stock Down 3.6 %

Shares of NASDAQ:PDSB opened at $1.32 on Wednesday. The firm has a market cap of $50.41 million, a PE ratio of -1.14 and a beta of 1.68. The company has a fifty day simple moving average of $1.41 and a 200 day simple moving average of $2.18. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 12-month low of $1.13 and a 12-month high of $4.92.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a research report on Thursday, March 13th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.67.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.